The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
about
Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseBiased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsIdentification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction.Systemic inflammation regulates microglial responses to tissue damage in vivomGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeAdenosinergic regulation of striatal clock gene expression and ethanol intake during constant lightDevelopment of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Molecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationDiscovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary MicrogliaPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsRecent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Overcoming obstacles in Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.Animal models of Parkinson's disease: a gateway to therapeutics?Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsGroup III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4.Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors.mGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice.Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild TypeMetabotropic glutamate receptors for Parkinson's disease therapy.Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).
P2860
Q26995351-2C9DFB45-3884-4AED-B19F-5D631522CFCCQ27305419-C5415D2C-00A8-4A48-AD06-92485E99E361Q30402875-6231B812-4379-40F7-BB60-2DE251485BA0Q30432649-B609D720-1712-4806-A57A-8E3E7E8782E8Q30643015-E2C41919-2DBD-41EB-817E-C27EF15C0ACAQ30821694-954C5997-1A9B-40BA-85D5-6A243CC22CE1Q34068934-C959DCBD-B290-46AD-B3F3-9A7BF520B305Q34373958-783EC0C5-9018-4175-B837-B4B7461783F3Q34399823-668BE9FA-3DC4-469D-B073-C3CF0A6A50CBQ34468639-2865A4FF-C9B2-4116-AED6-34B7E6C117C7Q34522043-FFFF8E0E-5902-43C6-B459-4FD7C393D005Q34534818-87F07324-0772-43CE-A5DE-BF1F511DD38EQ35124773-E2A3DC17-EA63-408A-AE71-D316CB62BB31Q35738538-845AE2D4-37B0-4976-8F44-3851CA10E443Q36203237-444BB2B5-98EB-44AD-BEC9-09214C498F53Q36844773-EE57DFA3-DEEF-434E-AA4C-E562EF380159Q37183072-CA0ABC21-6FF1-4414-92AA-723510A33C8AQ37999106-905388F1-F406-4DDB-BEF0-F9CAA14BFCB9Q38002888-161E3A0C-1151-4069-8A3B-1D9414263D9BQ38056852-49CA581B-E2E6-4773-B6B3-54494D80B3A6Q38056875-16826577-5189-4501-A587-041FFF7FEDA2Q38092819-2B9AE289-9A44-4193-A2C1-C6119EBE7073Q38139547-60589EC8-64AA-4AA6-BABD-D1C1F0CA7903Q38155480-976DACE7-CDE7-407F-B17E-EFAECEF2E651Q38190016-E13FE157-31B1-4F65-B8BD-9DA51B35B674Q38200930-907206E1-6ED3-4499-8AB6-C5FCE8DF9679Q38209092-DA6EFE54-BB19-431C-880C-73966B336E4CQ38242117-2A6DB613-4AC5-453B-8B99-28D871A30710Q38660240-E85AAC21-0F21-4A7E-92EC-265029FC9F34Q39085798-2FCA2987-005E-4332-B871-F1249C904BE9Q39378056-F412EA3D-E5FE-4B48-839A-728E6299D0F4Q40035243-3FD94489-10D4-4EEA-98F8-449ABE885A3CQ40435465-0673E9D3-5CBB-4AE7-B59B-CF975D0DE251Q41818450-D961E91D-118B-4615-9F89-2BC9AD08DCA7Q42145142-7E144E37-CA29-4AB4-86AB-C89FAA358295Q42271745-F389C686-FE78-4A62-9C52-4148FBA6D1C5Q42409715-71EBFF8C-B755-452A-8EEF-4426A444873D
P2860
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The metabotropic glutamate rec ...... models of Parkinson's disease.
@ast
The metabotropic glutamate rec ...... models of Parkinson's disease.
@en
type
label
The metabotropic glutamate rec ...... models of Parkinson's disease.
@ast
The metabotropic glutamate rec ...... models of Parkinson's disease.
@en
prefLabel
The metabotropic glutamate rec ...... models of Parkinson's disease.
@ast
The metabotropic glutamate rec ...... models of Parkinson's disease.
@en
P2093
P2860
P50
P356
P1476
The metabotropic glutamate rec ...... models of Parkinson's disease
@en
P2093
Analisa D Thompson
Anna L Blobaum
Carrie K Jones
Corey R Hopkins
Darren W Engers
J Scott Daniels
Jacob Bode
Jonathan W Dickerson
Kimberly Italiano
Nathalie Turle-Lorenzo
P2860
P304
P356
10.1124/JPET.111.187443
P407
P577
2011-11-16T00:00:00Z